Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$10 Mln
Revenue (TTM)
$0 Mln
Net Profit (TTM)
$0 Mln
ROE
-1.8 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
300.2
Industry P/E
--
EV/EBITDA
-0.5
Div. Yield
0 %
Debt to Equity
0
Book Value
$--
EPS
$--
Face value
--
Shares outstanding
64,532,100
CFO
$-345.41 Mln
EBITDA
$-402.04 Mln
Net Profit
$-435.02 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
GlycoMimetics (GLYC)
| -41.3 | -40.8 | -45.7 | -38.4 | -38.1 | -45.3 | -32.7 |
|
BSE Sensex*
| -13.4 | -9.8 | -13.9 | -3.6 | 7.5 | 7.9 | 11.2 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|---|---|---|---|---|---|---|---|
|
GlycoMimetics (GLYC)
| -89.3 | -22.1 | 110.4 | -61.7 | -28.9 | -44.1 | -43.4 |
|
S&P Small-Cap 600
| 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 | -9.7 |
|
BSE Sensex
| 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 | 5.9 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
GlycoMimetics, Inc. engages in the discovery and development of therapies for cancers and inflammatory diseases in the United States. The company was founded in 2003 and is based in Monrovia, Maryland.
CEO, President & Director
Mr. Harout Semerjian
CEO, President & Director
Mr. Harout Semerjian
Headquarters
Monrovia, MD
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of GlycoMimetics Inc (GLYC) is $14.62 (NASDAQ) as of 18-Jun-2025 09:30 EDT. GlycoMimetics Inc (GLYC) has given a return of -38.13% in the last 3 years.
Since, TTM earnings of GlycoMimetics Inc (GLYC) is negative, P/E ratio is not available.
The P/B ratio of GlycoMimetics Inc (GLYC) is 300.17 times as on 18-Jun-2025, a 7519 premium to its peers’ median range of 3.94 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2024
|
--
|
--
|
|
2023
|
--
|
--
|
|
2022
|
--
|
--
|
|
2021
|
--
|
--
|
|
2020
|
--
|
--
|
The 52-week high and low of GlycoMimetics Inc (GLYC) are Rs 63.00 and Rs 11.06 as of 03-Apr-2026.
GlycoMimetics Inc (GLYC) has a market capitalisation of $ 10 Mln as on 18-Jun-2025. As per SEBI classification, it is a Small Cap company.
Before investing in GlycoMimetics Inc (GLYC), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
$-1.08
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.